March 23, 2017 04:00 PM Eastern Daylight Time
NEW YORK--(BUSINESS WIRE)--Acuamark Diagnostics, Inc., a biotechnology company that focuses on developing accurate and cost-effective blood-based screening tests for the early detection of cancer, today announced the addition of Dr. Michael Hanbury to its Board of Directors.
Dr. Hanbury is a seasoned industry executive with over thirty years of clinical and corporate management experience in clinical laboratories and diagnostic companies. His broad career ranges from leading operations management in public and private clinical laboratories through development, engineering, compliance, clinical trials and regulatory affairs in in-vitro diagnostic manufacturing companies.
Dr. Hanbury states: “AcuamarkDx has brought together scientific advances in academic cancer research with novel amplification techniques focused on the early detection and monitoring of specific cancer markers. The company’s research and its cutting-edge, IP-protected detection chemistry present an exceptional opportunity to identify suspect cellular changes that may assist in identification of early-stage cancer. It is an honor to work along the respected members of management, the Board, and Dr. Francis Barany at Weill Cornell Medicine in this effort.”
Currently, Dr. Hanbury is a healthcare advisor for the Pritzker Group and is on a number of medical device company boards. Formerly, he was VP, Laboratory Operations and Laboratory Excellence for Quest Diagnostics, and President and Chief Operating Officer at Solstas Lab Partners, a high growth, regional clinical laboratory supported by Welsh, Carson, Anderson and Stowe. Earlier, he led the recapitalization of DCL Medical Laboratories as President and CEO, and significant growth phases as the EVP Operations and CSO at Unilab Corporation, formerly the third largest reference laboratory in the US with over 50 operating laboratories and revenue exceeding $650M. Overall, in his various roles as President, CEO and COO, Dr. Hanbury has directed technical laboratory operations with expense budgets in excess of $7B and has led technical operations for numerous laboratories across the country.
Dr. Bernard Peperstraete, CEO of Acuamark Diagnostics comments: "We are thrilled to welcome Michael into our midst. He is a fantastic individual and he enriches our Board with an all-round, in-depth industry expertise and a long track-record of success; his skill-sets range from deeply technical and quality control, to business development, and from regulatory to reimbursement."
Mr. Michael Gargano, Chairman of the Board of Acuamark Diagnostics, further adds: “We are pleased that Michael has chosen to join AcuamarkDx’s board. Michael’s operational and technological expertise will be a great asset to the company.”
About Acuamark Diagnostics Inc.
Acuamark Diagnostics is a biotechnology company focused on developing screening tests for blood-based early detection of cancer. Acuamark Diagnostics' technology allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team, it is Acuamark Diagnostics’ mission to contribute to the global battle against cancer by detecting and attacking cancer through high-precision, early detection.
Acuamark Diagnostics, Inc.
Bernard Peperstraete, MD
Chief Executive Officer